NEA Management Company’s Monte Rosa Therapeutics GLUE Stock Holding History

NEA Management Company’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$186M	Hold	7,692,298	–	–	11.72%	3
2026 Q1	$127M	Hold	7,692,298	–	–	7.19%	6
2025 Q4	$121M	Hold	7,692,298	–	–	6.15%	7
2025 Q3	$57M	Hold	7,692,298	–	–	3.13%	11
2025 Q2	$34.7M	Hold	7,692,298	–	–	2.61%	10
2025 Q1	$35.7M	Hold	7,692,298	–	–	2.75%	9
2024 Q4	$53.4M	Hold	7,692,298	–	–	3.01%	10
2024 Q3	$40.8M	Hold	7,692,298	–	–	2.22%	11
2024 Q2	$28.8M	Hold	7,692,298	–	–	2.16%	11
2024 Q1	$54.2M	Hold	7,692,298	–	–	3.37%	8
2023 Q4	$43.5M	Hold	7,692,298	–	–	2.9%	9
2023 Q3	$36.8M	Hold	7,692,298	–	–	2.85%	10
2023 Q2	$52.7M	Hold	7,692,298	–	–	4.02%	9
2023 Q1	$59.9M	Hold	7,692,298	–	–	4.14%	8
2022 Q4	$58.5M	Sell	7,692,298 -10,907	-0.1%	-$90.9K	3.29%	11
2022 Q3	$62.9M	Hold	7,703,205	–	–	3.14%	11
2022 Q2	$74.5M	Hold	7,703,205	–	–	3.83%	8
2022 Q1	$108M	Hold	7,703,205	–	–	3.12%	7
2021 Q4	$157M	Hold	7,703,205	–	–	3.18%	7
2021 Q3	$172M	Hold	7,703,205	–	–	2.04%	8
2021 Q2	$175M	Buy	+7,703,205	New	+$157M	2.28%	8

Other funds holding GLUE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

NEA Management Company's GLUE Position: Q2 2026 in Review

NEA Management Company held its Monte Rosa Therapeutics (GLUE) position steady in Q2 2026 at 7,692,298 shares worth $186M. The position accounts for 11.72% of the portfolio, ranked #3.

NEA Management Company first reported a position in GLUE in Q2 2021 and has held it in 21 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

NEA Management Company held 7,692,298 shares of Monte Rosa Therapeutics worth $186M as of Q2 2026.
NEA Management Company left its Monte Rosa Therapeutics share count unchanged in Q2 2026.
Monte Rosa Therapeutics made up 11.72% of NEA Management Company's portfolio in Q2 2026, its #3 holding.
NEA Management Company first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 21 quarters since.
193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on NEA Management Company's 13F filing for Q2 2026, filed 14 Aug 2026.